3 Market Leaders to Own Beyond the 'Magnificent 7' Stocks

 | Feb 09, 2024 10:57

  • The stock market continues to rally to new heights, with the S&P 500 hitting the 5,000-mark for the first time in history.
  • While most of the focus is on the ‘Magnificent 7’ mega-cap tech stocks there are quite a few companies that have seen their shares climb to new highs.
  • As such, investors should consider adding the three stocks we plan to discuss in this article to their portfolio as the stock market rally continues.
  • In 2024, invest like the big funds from the comfort of your home with our AI-powered ProPicks stock selection tool.
  • In a market dominated by the 'Magnificent 7' group of mega-cap tech stocks, investors often overlook other market leaders poised for significant growth.

    By diversifying beyond Nvidia (NASDAQ:NVDA), Microsoft (NASDAQ:MSFT), Meta (NASDAQ:META), Amazon (NASDAQ:AMZN), Alphabet (NASDAQ:GOOG), Apple (NASDAQ:AAPL), and Tesla (NASDAQ:TSLA), investors can potentially unlock significant returns.

    Fortunately, our innovative predictive AI stock-picking tool, ProPicks, is here to assist you in identifying such opportunities. With a track record of success backed by six strategies that consistently outperform the market, ProPicks integrates historical stock market data with cutting-edge fundamental analysis techniques to presents over 70 potential winning stocks every month.

    Join now for under $9 a month for a limited time only and never miss another bull market by not knowing which stocks to buy!

    • *Readers of this article enjoy an extra 10% discount on the yearly and by-yearly plans with the coupon code UKTopDiscount (yearly & bi-yearly).

    While the 'Magnificent 7' stocks may dominate headlines, investors should not overlook this trio of market leaders with strong growth prospects.

    h2 1. Eli Lilly/h2

    Eli Lilly's (NYSE:LLY) robust portfolio of blockbuster drugs, coupled with its focus on research and development, positions it for sustained growth, making it a compelling investment choice beyond the 'Magnificent 7' stocks.

    Investors have placed high hopes on the pharmaceutical company’s progress with its promising obesity drug pipeline. Lilly’s hopeful candidates in Alzheimer's disease and immunology have also boosted investor confidence.

    The pharma giant has experienced a surge in its stock price over the past year, driven by strong sales growth in key therapeutic areas.

    Shares of the Indianapolis, Indiana-based healthcare juggernaut, which ended at an all-time high of $735.68 last night, are up 116% over the past 12 months.